Stock PAX PAXMAN AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Paxman AB

Equities

PAX

SE0009806284

Delayed Nasdaq Stockholm
Other stock markets
 06:59:47 2024-04-30 am EDT 		5-day change 1st Jan Change
35.8 SEK -4.53% Intraday chart for Paxman AB +1.99% -2.72%
Jan. 15 Paxman AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Paxman AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company is in a robust financial situation considering its net cash and margin position.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.8 times its estimated earnings per share for the ongoing year.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
PAXMAN AB Stock Paxman AB
-2.72% 61.97M
D
ABBOTT LABORATORIES Stock Abbott Laboratories
-3.39% 184B
C+
MEDTRONIC PLC Stock Medtronic plc
-2.44% 107B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-3.78% 67.78B
A
DEXCOM, INC. Stock DexCom, Inc.
+1.83% 50.66B
B-
CENCORA, INC. Stock Cencora, Inc.
+10.46% 47.64B
B-
HOYA CORPORATION Stock Hoya Corporation
+4.60% 41.12B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+1.62% 26.3B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+1.75% 26.04B
A-
TERUMO CORPORATION Stock Terumo Corporation
+15.06% 25.4B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy
  1. Stock Market
  2. Equities
  3. PAX Stock
  4. Ratings Paxman AB